Potential Anti-Allergy and Immunomodulatory Properties of Lactococcus lactis LB 1022 Observed In Vitro and in an Atopic Dermatitis Mouse Model
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Lactococcus lactis is a lactic acid bacterium and used in the dairy food industry. The ameliorating effects of Lactobacillus species on atopic dermatitis (AD) have been extensively studied, but the specific effect of L. lactis strains has not yet been investigated. In this study, the efficacy of L. lactis LB 1022, isolated from natural cheese, was evaluated using RAW 264.7, HMC-1 and HaCaT cell lines and an ovalbumin-sensitized AD mouse model. L. lactis LB 1022 exhibited nitric oxide suppression and anti-allergy and anti-inflammatory activity in vitro. Oral administration of L. lactis LB 1022 to AD mice significantly reduced the levels of IgE, mast cells, and eosinophils, and a range of T cell-mediated T helper Th1, Th2, and Th17-type cytokines under interleukin (IL)-10, transforming growth factor-β (TGF-β), thymus and activation-regulated chemokine (TARC), and thymic stromal lymphopoietin (TSLP). In addition, L. lactis LB 1022 treatment increased the concentration of short-chain fatty acids. Overall, L. lactis LB 1022 significantly modulated AD-like symptoms by altering metabolites and the immune response, illustrating its potential as candidate for use in functional food supplements to alleviate AD.
Abstract
Lactococcus lactis is a lactic acid bacterium and used in the dairy food industry. The ameliorating effects of Lactobacillus species on atopic dermatitis (AD) have been extensively studied, but the specific effect of L. lactis strains has not yet been investigated. In this study, the efficacy of L. lactis LB 1022, isolated from natural cheese, was evaluated using RAW 264.7, HMC-1 and HaCaT cell lines and an ovalbumin-sensitized AD mouse model. L. lactis LB 1022 exhibited nitric oxide suppression and anti-allergy and anti-inflammatory activity in vitro. Oral administration of L. lactis LB 1022 to AD mice significantly reduced the levels of IgE, mast cells, and eosinophils, and a range of T cell-mediated T helper Th1, Th2, and Th17-type cytokines under interleukin (IL)-10, transforming growth factor-β (TGF-β), thymus and activation-regulated chemokine (TARC), and thymic stromal lymphopoietin (TSLP). In addition, L. lactis LB 1022 treatment increased the concentration of short-chain fatty acids. Overall, L. lactis LB 1022 significantly modulated AD-like symptoms by altering metabolites and the immune response, illustrating its potential as candidate for use in functional food supplements to alleviate AD.
참고문헌 (29)
- Zhu TH, "Epithelial barrier dysfunctions in atopic dermatitis : a skin-gut-lung model linking microbiome alteration and immune dysregulation", Br. J. Dermatol, 179, pp.570~581 (2018)
- Petersen EBM, "Role of the gut microbiota in atopic dermatitis : A systematic review", Acta Derm. Venereol, 99, pp.5~11 (2019)
- 이소연, "Microbiome in the Gut-Skin Axis in Atopic Dermatitis", Allergy, Asthma & Immunology Research, 10(4), pp.354~362 (2018), 대한천식알레르기학회
- Yamamoto K, "Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with atopic dermatitis", J. Dairy Sci, 99, pp.5039~5046 (2016)
- Reddel S, "Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture", Sci. Rep, 9, pp.4996~ (2019)
- Anania C, "Probiotics function in preventing atopic dermatitis in children", Int. J. Mol. Sci, 23, pp.5409~ (2022)
- Song AA, "A review on Lactococcus lactis : from food to factory", Microb. Cell Fact, 16, pp.55~ (2017)
- Ghasemzadeh J, "Effects of dietary probiotic, Lactococcus lactis “subspecies PTCC 1403” on the growth parameters and survival rate of grey mullet (Mugil cephalus L.) against Lactococcus garvieae bacteria", J. Anim. Environ. Sci, 10, pp.367~374 (2018)
- Yoshida A, "Oral administration of live Lactococcus lactis C59 suppresses IgE antibody production in ovalbumin-sensitized mice via the regulation of interleukin-4 production", FEMS Immunol. Med. Microbiol, 61, pp.315~322 (2011)
- Cervantes-Garcia D, "Lactococcus lactis NZ9000 prevents asthmatic airway inflammation and remodelling in rats through the improvement of intestinal barrier function and systemic TGF-beta production", Int. Arch. Allergy Immunol, 182, pp.277~291 (2021)
- Konkit M, "Alcohol dehydrogenase activity in Lactococcus chungangensis: application in cream cheese to moderate alcohol uptake", J. Dairy Sci, 98, pp.5974~5982 (2015)
- Frank JA, "Critical evaluation of two primers commonly used for amplification of bacterial 16S rRNA genes", Appl. Environ. Microbiol, 74, pp.2461~2470 (2008)
- Robbins KS, "Effect of pecan phenolics on the release of nitric oxide from murine RAW 264.7macrophage cells", Food Chem, 212, pp.681~687 (2016)
- Mosmann T, "Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays", J. Immunol. Methods, 65, pp.55~63 (1983)
- Kim JH, "Alleviation effects of Rubus coreanus Miquel root extract on skin symptoms and inflammation in chronic atopic dermatitis", Food Funct, 13, pp.2823~2831 (2022)
- Luerce TD, "Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis", Gut Pathog, 6, pp.33~ (2014)
- Liu M, "Protective effects of a novel probiotic strain, Lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence", Food Funct, 10, pp.1132~1145 (2019)
- Penders J, "The role of the intestinal microbiota in the development of atopic disorders", Allergy, 62, pp.1223~1236 (2007)
- 김하정, "Antibiotics-Induced Dysbiosis of Intestinal Microbiota Aggravates Atopic Dermatitis in Mice by Altered Short-Chain Fatty Acids", Allergy, Asthma & Immunology Research, 12(1), pp.137~148 (2020), 대한천식알레르기학회
- Choi WJ, "Oral administration of Lactococcus chungangensis inhibits 2,4-dinitrochlorobenzene-induced atopic-like dermatitis in NC", Nga mice, 2016, pp.99, 6889~6901
- Kim JH, "Cream Cheese-Derived Lactococcus chungangensis CAU 28 modulates the gut microbiota and alleviates atopic dermatitis in BALB", c mice, 2019, pp.9, 446~
- Bieber T, "Atopic dermatitis: an expanding therapeutic pipeline for a complex disease", Nat. Rev. Drug Discov, 21, pp.21~40 (2022)
- Yamanaka K-i, "The role of cytokines", chemokines in the pathogenesis of atopic dermatitis, 2011, pp.41, 80~92
- Brandt EB, "Th2 cytokines and atopic dermatitis", J. Clin. Cell. Immunol, 2, pp.110~ (2011)
- Smits HH, "Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin", J. Allergy Clin. Immunol, 115, pp.1260~1267 (2005)
- Zhang N, "Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response", Immunity, 30, pp.458~469 (2009)
- Koh A, "From dietary fiber to host physiology : Short-chain fatty acids as key bacterial metabolites", Cell, 165, pp.1332~1345 (2016)
- Maslowski KM, "Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43", Nature, 461, pp.1282~1286 (2009)
- Kim Jong-Hwa, "Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy", Experimental and Molecular Medicine, 53, pp.1~10 (2021), 생화학분자생물학회[DOI]
